Treatment of Candida famata bloodstream infections: Case series and review of the literature

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 2, 2013, Pages 438-443

  Beyda, Nicholas D ^a,b   Chuang, Shen Hui ^c   Jahangir Alam, M ^a   Shah, Dhara N ^a,b   Ng, Tat Ming ^c   McCaskey, Laurie ^b   Garey, Kevin W ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Candida bloodstream infections; Echinocandins; Literature review; Strain typing; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CYTARABINE; ECHINOCANDIN; ETOPOSIDE; FLUCONAZOLE; FLUCYTOSINE; IDARUBICIN; ITRACONAZOLE; MICAFUNGIN; MITOXANTRONE; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; BONE MARROW BIOPSY; CANDIDA FAMATA; CASE REPORT; CENTRAL VENOUS CATHETER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FUNGEMIA; GENOTYPE; HOSPITAL PATIENT; HUMAN; MALE; NONHUMAN; PSEUDOMONAS INFECTION; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CATHETER-RELATED INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84872379393     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks388     Document Type: Article

References (26)

1. Gardini F, Suzzi G, Lombardi A et al. A survey of yeasts in traditional sausages of southern Italy. FEMS Yeast Res 2001; 1: 161-7.
2. Kam AP, Xu J. Diversity of commensal yeasts within and among healthy hosts. Diagn Microbiol Infect Dis 2002; 43: 19-28.
3. Ahmed IM, Gupta A, Gould K et al. A fatal fungus. Ann Thorac Surg 2005; 80: 723-4.
4. Gupta A, Mi H, Wroe C et al. Fatal Candida famata peritonitis complicating sclerosing peritonitis in a peritoneal dialysis patient. Nephrol Dial Transplant 2006; 21: 2036-7.
5. Pisa D, Ramos M, Garcia P et al. Fungal infection in patients with serpiginous choroiditis or acute zonal occult outer retinopathy. J Clin Microbiol 2008; 46: 130-5.
6. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-77.
7. Kawakami S, Ono Y, Miyazawa Y et al. [Survey of fungemia cases during the past seventeen years at Teikyo University Hospital]. Kansenshogaku Zasshi 1998; 72: 105-13.
8. Pfaller MA, Diekema DJ, Messer SA et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78-83.
9. Pfaller MA, Diekema DJ, Messer SA et al. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47: 1068-71.
10. Shah DN, Yau R, Lasco TM et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother 2012; 56: 3239-43.
11. Shah DN, Yau R, Weston J et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011; 66: 2146-51.
12. Liguori G, Lucariello A, Colella G et al. Rapid identification of Candida species in oral rinse solutions by PCR. J Clin Pathol 2007; 60: 1035-9.
13. Carrega G, Riccio G, Santoriello L et al. Candida famata fungemia in a surgical patient successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis 1997; 16: 698-9.
14. Turunc T, Demiroglu YZ, Aliskan H et al. [Retrospective evaluation of the cases with Candida famata fungemia in a burn unit]. Mikrobiyol Bul 2009; 43: 71-6.
15. Wagner D, Sander A, Bertz H et al. Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection 2005; 33: 397-400.
16. Liu CY, Huang LJ, Wang WS et al. Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. J Infect 2009; 58: 154-60.
17. Arevalo MP, Carrillo-Munoz AJ, Salgado J et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003; 51: 163-6.
18. Luo G, Peng Y, Yuan Z et al. Yeast from burn patients at a major burn centre of China. Burns 2011; 37: 299-303.
19. Ozcelik B, Kaynak F, Cesur S et al. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens. Jpn J Infect Dis 2007; 60: 302-4.
20. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6.
21. Pfaller MA, Diekema DJ, Messer SA et al. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis 2004; 48: 101-5.
22. Barchiesi F, Tortorano AM, Di Francesco LF et al. In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J Antimicrob Chemother 1999; 43: 295-9.
23. Garcia-Effron G, Katiyar SK, Park S et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-12.
24. Nishikawa A, Sugita T, Shinoda T. Differentiation between Debaryomyces hansenii/Candida famata complex and Candida guilliermondii by polymerase chain reaction. FEMS Immunol Med Microbiol 1997; 19: 125-9.
25. Nishikawa A, Tomomatsu H, Sugita T et al. Taxonomic position of clinical isolates of Candida famata. J Med Vet Mycol 1996; 34: 411-9.
26. Desnos-Ollivier M, Ragon M, Robert V et al. Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol 2008; 46: 3237-42.